|
| 35012410 | Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. | J Asthma | 2023 |
| 37516531 | A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. | Value Health | 2023 |
| 37181704 | Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment. | Front Public Health | 2023 |
| 37042868 | Investigations on the cytotoxicity and antimicrobial activities of terezine E and 14-hydroxyterezine D. | Braz J Med Biol Res | 2023 |
| 37380118 | Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review. | J Clin Epidemiol | 2023 |
| 37342987 | Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. | Clin Pharmacol Ther | 2023 |
| 37010791 | Cubic nanoparticles as potential carriers for a natural anticancer drug: development, in vitro and in vivo characterization. | Drug Deliv Transl Res | 2023 |
| 37006486 | Participating in innovative medicines initiative funded neurodegenerative disorder projects-An impact analysis conducted as part of the NEURONET project. | Front Neurol | 2023 |
| 37465169 | Recommendations for patient involvement in health technology assessment in Central and Eastern European countries. | Front Public Health | 2023 |
| 37092749 | Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations. | Int J Technol Assess Health Care | 2023 |
| 36855929 | Synergy between health technology assessments and clinical guidelines for multiple sclerosis. | Clin Transl Sci | 2023 |
| 36919494 | Comparative study on the performance of monoolein cubic nanoparticles and trimyristin solid lipid nanoparticles as carriers for docetaxel. | Pharm Dev Technol | 2023 |
| 36797052 | Living health technology assessments: how close to living reality? | BMJ Evid Based Med | 2023 |
| 36861458 | Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making. | J Comp Eff Res | 2023 |
| 36162195 | Estimating Societal Cost of Illness and Patients' Quality of Life of Duchenne Muscular Dystrophy in Egypt. | Value Health Reg Issues | 2023 |
| 35332434 | Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges. | Pharmacoeconomics | 2022 |
| 35645790 | A Review of Economic Models Submitted to NICE's Technology Appraisal Programme, for Treatments of T1DM & T2DM. | Front Pharmacol | 2022 |
| 35345821 | Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. | Clin Epidemiol | 2022 |
| 35392566 | Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design. | Front Pharmacol | 2022 |
| 35419763 | Correction to: New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. | Clin Rheumatol | 2022 |
| 36408524 | The Innovative Medicines Initiative neurodegeneration portfolio: From individual projects to collaborative networks. | Front Neurol | 2022 |
| 36438785 | Institutionalizing health technology assessment in Egypt: Situational analysis and roadmap. | Front Pharmacol | 2022 |
| 36452232 | Editorial: Women in drugs outcomes research and policies: 2021. | Front Pharmacol | 2022 |
| 36213666 | Outcome-based reimbursement in Central-Eastern Europe and Middle-East. | Front Med (Lausanne) | 2022 |
| 35968493 | Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries. | Front Public Health | 2022 |
| 36035424 | Delayed payment schemes in Central-Eastern Europe and Middle-East. | Front Med (Lausanne) | 2022 |
| 36220321 | Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE. | BMJ Open | 2022 |
| 33768474 | Ion exchange column technique as a novel method for evaluating the release of docetaxel from different lipid nanoparticles. | Drug Deliv Transl Res | 2022 |
| 35247152 | Capturing what matters: updating NICE methods guidance on measuring and valuing health. | Qual Life Res | 2022 |
| 35181207 | Diagnostics and Treatments of COVID-19: A Living Systematic Review of Economic Evaluations. | Value Health | 2022 |
| 32405277 | Emerging from the other end: Key measures for a successful COVID-19 lockdown exit strategy and the potential contribution of pharmacists. | Res Social Adm Pharm | 2021 |
| 33725121 | COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. | Rheumatology (Oxford) | 2021 |
| 33688639 | Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. | Res Sq | 2021 |
| 34937726 | Characteristics and outcomes of patients with COVID-19 with and without prevalent hypertension: a multinational cohort study. | BMJ Open | 2021 |
| 34526320 | Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. | BMJ | 2021 |
| 34635993 | Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop. | Pharmacoeconomics | 2021 |
| 34272262 | Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34267326 | Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. | Int J Obes (Lond) | 2021 |
| 33975825 | Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. | BMJ | 2021 |
| 34254275 | The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review. | Appl Health Econ Health Policy | 2021 |
| 33336320 | Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. | Pharmacoeconomics | 2021 |
| 33070296 | Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes. | Int J Clin Pharm | 2021 |
| 32912829 | Pharmacy practice research priorities during the COVID-19 pandemic: Recommendations of a panel of experts convened by FIP Pharmacy Practice Research Special Interest Group. | Res Social Adm Pharm | 2021 |
| 32792322 | Drive-thru pharmacy services: A way forward to combat COVID-19 pandemic. | Res Social Adm Pharm | 2021 |
| 31101458 | Generosity, collegiality, and scientific accuracy when writing and reviewing original research. | Res Social Adm Pharm | 2020 |
| 32057690 | Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries. | Res Social Adm Pharm | 2020 |
| 32041284 | Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population. | Int J Environ Res Public Health | 2020 |
| 32034553 | New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. | Clin Rheumatol | 2020 |
| 33274643 | USA stockpiling of remdesivir: How should the world respond? | J Comp Eff Res | 2020 |
| 33269355 | Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis. | medRxiv | 2020 |